A new clinical study to reduce the unwanted side effects of radiation in patients with human papillomavirus (HPV)—positive oropharynx cancers has found that reducing the dose of radiation can maintain the cure rates but avoid some of the late treatment-associated toxicities.
A new clinical study to reduce the unwanted side effects of radiation in patients with human papillomavirus (HPV)—positive oropharynx cancers has found that reducing the dose of radiation can maintain the cure rates but avoid some of the late treatment-associated toxicities.
HPV-positive oropharynx cancers develop in the tonsils and the back of the throat. Radiation administered to treat these cancers often results in sever issues with swallowing, eating, and nutrition. The questions is, can these toxicities be avoided while maintaining the cure rate?
To test this hypothesis, researchers enrolled 80 patients from 16 ECOG-ACRIN Cancer Research Group sites, who were diagnosed with stage 3 or 4 HPV—positive squamous cell carcinoma of the oropharynx. Patients received 3 courses of induction chemotherapy with cisplatin, paclitaxel, and cetuximab. Those who had a good clinical response then received reduced doses of radiation. Those who received lower dose of radiation had less difficulty swallowing solid food compared with those who received the regular dose (40% versus 89%, respectively). Further, only 10% of those who received the lower dose had impaired nutrition, compared with 44% of those who received the regular radiation dose.
Considering that a lot of younger patients are presenting with HPV-positive squamous cell carcinoma of the oropharynx, their long-term quality of life is extremely important. “Younger patients may have to deal with these side effects for decades after cancer treatment. We want to help improve our patients’ quality of life,” said Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital.
The study has been published in the Journal of Clinical Oncology.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More